The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.a

Respiratory tract infection incl. pneumonia

Publications

O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

The Lancet. Oncology 2016 Oct;17;1409-1418 — 2016 Oct — 1409-1418

Link CS, Teipel R, Heidenreich F, Rücker-Braun E, Schmiedgen M, Reinhardt J, Oelschlägel U, von Bonin M, Middeke JM, Muetherig A, Trautmann-Grill K, Platzbecker U, Bornhäuser M, Schetelig J

Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Bone marrow transplantation 2016 Jun;51;793-8 — 2016 Jun — 793-8

Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM,

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Blood 2015 Aug 06;126;739-45 — 2015 Aug 06 — 739-45